New research suggests that people who discontinue popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Findings released in a major health publication points out that while overweight individuals often shed about a fifth of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such drugs need to be informed of the danger of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting mass in about one and a half years.
Weighing Treatments
The research, which examined 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Scientists emphasize that individuals who shed pounds through diet and exercise generally experience a less rapid creep back—approximately 100 grams monthly—post-intervention.
Understanding the Fast Rebound
Nutrition scientists suggest the mechanism of the drugs is key to understanding the amplified weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making overeating a significant risk."
A Chronic Disease?
The NHS suggest the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the high risk of relapse, the therapy should be considered long-term.
This opinion is reinforced by drug manufacturers, who state that the findings "underscore the long-term nature of obesity," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have discontinued the medication explain a intense return of cravings.
"It felt as if a switch flipping and you're instantly extremely hungry," said one woman.
This challenge is compounded if patients have not developed permanent lifestyle or habit changes during treatment.
Growing Adoption
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic cure and maintained weight loss relies on combined lifestyle support.
